BACKGROUND: Interindividual differences in DNA repair capacity may influence cancer risk. We tested whether the nucleotide excision repair pathway was deficient in breast cancer case patients by analyzing sister pairs. METHODS: Cell lines derived from sisters discordant for breast cancer (137 families containing 158 case patients and 154 control sisters) were obtained from the Metropolitan New York Registry of Breast Cancer Families. Lymphoblastoid cells were treated with benzo[a]pyrene diolepoxide (BPDE) for 30 minutes and were either harvested immediately or were washed and cultured in complete medium for 4 hours to allow DNA repair. Immunofluorescence using a polyclonal anti-BPDE-DNA primary antibody was used to quantify BPDE-DNA adducts. Percent DNA repair capacity was calculated from the difference between staining immediately after treatment minus that after 4 hours of repair, divided by the initial damage and was categorized into quartiles based on control values. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression models adjusted for age at blood donation, body mass index, and smoking. Statistical tests were two-sided. RESULTS: Mean percent DNA repair capacity was lower in breast cancer case patients than in control subjects (difference = 8.6, 95% CI = 4.3 to 13.8, P = .001). Using the quartile with the highest percent DNA repair capacity as the referent group, adjusted odds ratios of breast cancer increased from 1.23 (95% CI = 0.57 to 2.65) to 2.38 (95% CI = 1.17 to 4.86) to 2.99 (95% CI = 1.45 to 6.17) (P(trend) = .002) as DNA repair capacity decreased. CONCLUSIONS: Deficient DNA repair capacity is associated with increased breast cancer risk.
BACKGROUND: Interindividual differences in DNA repair capacity may influence cancer risk. We tested whether the nucleotide excision repair pathway was deficient in breast cancer case patients by analyzing sister pairs. METHODS: Cell lines derived from sisters discordant for breast cancer (137 families containing 158 case patients and 154 control sisters) were obtained from the Metropolitan New York Registry of Breast Cancer Families. Lymphoblastoid cells were treated with benzo[a]pyrene diolepoxide (BPDE) for 30 minutes and were either harvested immediately or were washed and cultured in complete medium for 4 hours to allow DNA repair. Immunofluorescence using a polyclonal anti-BPDE-DNA primary antibody was used to quantify BPDE-DNA adducts. Percent DNA repair capacity was calculated from the difference between staining immediately after treatment minus that after 4 hours of repair, divided by the initial damage and was categorized into quartiles based on control values. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression models adjusted for age at blood donation, body mass index, and smoking. Statistical tests were two-sided. RESULTS: Mean percent DNA repair capacity was lower in breast cancer case patients than in control subjects (difference = 8.6, 95% CI = 4.3 to 13.8, P = .001). Using the quartile with the highest percent DNA repair capacity as the referent group, adjusted odds ratios of breast cancer increased from 1.23 (95% CI = 0.57 to 2.65) to 2.38 (95% CI = 1.17 to 4.86) to 2.99 (95% CI = 1.45 to 6.17) (P(trend) = .002) as DNA repair capacity decreased. CONCLUSIONS: Deficient DNA repair capacity is associated with increased breast cancer risk.
Authors: Nicola Machella; Mary Beth Terry; Jennifer Zipprich; Irina Gurvich; Yuyan Liao; Ruby T Senie; David O Kennedy; Regina M Santella Journal: Carcinogenesis Date: 2008-06-19 Impact factor: 4.944
Authors: Lissette Delgado-Cruzata; Hui-Chen Wu; Yuyan Liao; Regina M Santella; Mary Beth Terry Journal: Epigenetics Date: 2013-10-29 Impact factor: 4.528
Authors: Pierre R Bushel; Ray McGovern; Liwen Liu; Oliver Hofmann; Ahsan Huda; Jun Lu; Winston Hide; Xihong Lin Journal: PLoS One Date: 2012-03-27 Impact factor: 3.240
Authors: Rick J Jansen; Sharon Fonseca-Williams; William R Bamlet; Sylvette Ayala-Peña; Ann L Oberg; Gloria M Petersen; Carlos A Torres-Ramos Journal: Mol Carcinog Date: 2014-08-11 Impact factor: 4.784
Authors: Maryann Donovan; Tiffany D Miles; Jean J Latimer; Stephen Grant; Evelyn Talbott; Annie J Sasco; Devra L Davis Journal: Nat Rev Cancer Date: 2006-08 Impact factor: 60.716
Authors: Stephen G Grant; Rubina Das; Christina M Cerceo; Wendy S Rubinstein; Jean J Latimer Journal: Pathol Oncol Res Date: 2007-12-25 Impact factor: 3.201
Authors: Jennifer Zipprich; Mary Beth Terry; Paul Brandt-Rauf; Greg A Freyer; Yuyan Liao; Meenakshi Agrawal; Irina Gurvich; Ruby Senie; Regina M Santella Journal: J Carcinog Date: 2010-04-16